Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2005-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-004-0615-8PMID 15692847PMCID PMC11042490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report.

  2004cited by this paper
• Control of cross‐presentation during dendritic cell maturation

  2004cited by this paper
• Requirements for T Cell-Polarized Tubulation of Class II+ Compartments in Dendritic Cells 1

  2003cited by this paper
• Promiscuity of MHC Class Ib-Restricted T Cell Responses 1

  2003cited by this paper
• Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells

  2003cited by this paper
• Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

  2003cited by this paper
• Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality 1

  2003cited by this paper
• Transcriptional expression of survivin and its splice variants in brain tumors in humans.

  2003cited by this paper
• Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

  2003cited by this paper
• Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1

  2003cited by this paper
• Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.

  2003cited by this paper
• Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain

  2002cited by this paper
• Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells

  2002cited by this paper
• Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

  2002cited by this paper
• 7-Hydroxystaurosporine-induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells and Yields a Potent Vaccine Strategy in an Intracranial Glioma Model

  2002cited by this paper
• Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

  2002cited by this paper
• The two faces of IL-6 on Th1/Th2 differentiation.

  2002cited by this paper
• An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity.

  2002cited by this paper
• The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells1

  2002cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production.

  2001cited by this paper
• Cutting Edge: The Dendritic Cell Cytoskeleton Is Critical for the Formation of the Immunological Synapse1

  2001cited by this paper
• Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

  2001cited by this paper
• A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity.

  2001cited by this paper
• Dendritic cells: specialized and regulated antigen processing machines.

  2001cited by this paper
• The use of dendritic cells in cancer therapy.

  2001cited by this paper
• Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells

  2001cited by this paper
• Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.

  2000cited by this paper
• Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.

  2000cited by this paper
• Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor

  2000cited by this paper
• Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides

  2000cited by this paper
• Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.

  2000cited by this paper
• Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.

  2000cited by this paper
• Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.

  2000influential reference
• In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.

  2000cited by this paper
• Degradation of cell proteins and the generation of MHC class I-presented peptides.

  1999cited by this paper
• Immune selection after antigen-specific immunotherapy of melanoma.

  1999cited by this paper
• Immune defects observed in patients with primary malignant brain tumors.

  1999cited by this paper
• Expression of the tumor‐rejection antigen SART1 in brain tumors

  1999cited by this paper
• Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

  1999cited by this paper
• Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers.

  1999cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• Estimation of the frequencies of anti‐MAGE‐3 cytolytic T‐lymphocyte precursors in blood from individuals without cancer

  1998influential reference
• Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

  1998influential reference
• Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells

  1997cited by this paper
• Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

  1997influential reference
• Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.

  1997cited by this paper
• T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors.

  1997cited by this paper
• Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro.

  1997cited by this paper
• Dendritic Cell Development: Multiple Pathways to Nature's Adjuvants

  1997cited by this paper
• Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.

  1996cited by this paper
• Tumor antigens in astrocytic gliomas

  1995cited by this paper
• Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

  1994cited by this paper
• A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3

  1994influential reference
• Tenascin expression in human glioma cell lines and normal tissues.

  1992cited by this paper
• Inflammatory leukocytes associated with increased immunosuppression by glioblastoma.

  1992cited by this paper
• Presentation of exogenous antigen with class I major histocompatibility complex molecules.

  1990cited by this paper
• Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

  1989cited by this paper
• Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas.

  1987cited by this paper
• Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells.

  1982influential reference
• Heterogeneity of Genotypic and Phenotypic Characteristics of Fifteen Permanent Cell Lines Derived from Human Gliomas

  1981cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients.

  2024cites this paper
• Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma

  2023cites this paper
• Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

  2021cites this paper
• Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells

  2021cites this paper
• Understanding and Improving Cellular Immunotherapies Against Cancer: From Cell-Manufacturing to Tumor-Immune Models.

  2021cites this paper
• Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

  2020cites this paper
• Proof of Concept Study: Mesoporous Silica Nanoparticles, From Synthesis to Active Specific Immunotherapy

  2020cites this paper
• Rapid mechanochemical encapsulation of biocatalysts into robust metal–organic frameworks

  2019cites this paper
• Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy

  2019cites this paper
• Gearing up T-cell immunotherapy in cervical cancer.

  2018cites this paper
• A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination – A Review

  2017cites this paper
• Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival

  2017cites this paper
• Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas.

  2016cites this paper
• Brain Tumor Immunotherapy: What have We Learned so Far?

  2015cites this paper
• Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review

  2014cites this paper
• Wilms' tumor gene 1 as an immunotherapeutic target in uterine cancer

  2014cites this paper
• Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

  2013cites this paper
• Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.

  2013cites this paper
• CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy

  2013cites this paper
• Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

  2012cites this paper
• Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

  2012cites this paper
• Immunotherapy for Malignant Gliomas: A Roadmap for the Future

  2011cites this paper
• Wilms’ Tumour gene 1 (WT1) as an immunotherapeutic target

  2011cites this paper
• Dendritic cell-based tumor vaccination for high-grade gliomas

  2011cites this paper
• Galectin-1 and immunotherapy for brain cancer

  2011cites this paper
• Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

  2010cites this paper
• Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.

  2010cites this paper
• Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours

  2010cites this paper
• Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models

  2010cites this paper
• Vaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in mice.

  2010cites this paper
• 树突状细胞的体外培养及其抗癌作用

  2010cites this paper
• The dendritic therapy with its potential applications in pancreatic cancer.

  2009cites this paper
• Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro

  2009cites this paper
• The dendritic therapy with its potential applications in pancreatic cancer.

  2009cites this paper
• Dendritic Cell Therapy of High‐Grade Gliomas

  2009influential citation
• DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

  2009cites this paper
• Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation.

  2008cites this paper
• Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

  2008cites this paper
• Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model.

  2007cites this paper
• Dendritic cell-based active specific immunotherapy for malignant glioma

  2007cites this paper
• Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.

  2007cites this paper
• Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells

  2007cites this paper
• Current State and Perspectives of Dendritic Cell Vaccination in Cancer Immunotherapy

  2006cites this paper
• DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS: CURRENT STATUS AND FUTURE DIRECTIONS

  2006cites this paper
• Current status of clinical trials for glioblastoma.

  2006cites this paper
• [Dendritic cells and gliomas: a hope in immunotherapy?].

  2006cites this paper
• Cellules dendritiques et gliomes : un espoir en immunothérapie ?

  2006cites this paper
• Effects of cytotoxic T lymphocytes on hepatoma cell line SMMC-7721 induced by different subsets of dendritic cells in vitro.

  2006cites this paper